Cargando…
COVID‐19 diagnostic testing: Technology perspective
The corona virus disease 2019 (COVID‐19) is a highly contagious disease caused by the severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2). More than 18 million people were infected with a total of 0.7 million deaths in ∼188 countries. Controlling the spread of SARS‐CoV‐2 is therefore inhere...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7443140/ https://www.ncbi.nlm.nih.gov/pubmed/32898340 http://dx.doi.org/10.1002/ctm2.158 |
_version_ | 1783573576158281728 |
---|---|
author | Xu, Meng Wang, Dan Wang, Hongye Zhang, Xiaomei Liang, Te Dai, Jiayu Li, Meng Zhang, Jiahui Zhang, Kai Xu, Danke Yu, Xiaobo |
author_facet | Xu, Meng Wang, Dan Wang, Hongye Zhang, Xiaomei Liang, Te Dai, Jiayu Li, Meng Zhang, Jiahui Zhang, Kai Xu, Danke Yu, Xiaobo |
author_sort | Xu, Meng |
collection | PubMed |
description | The corona virus disease 2019 (COVID‐19) is a highly contagious disease caused by the severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2). More than 18 million people were infected with a total of 0.7 million deaths in ∼188 countries. Controlling the spread of SARS‐CoV‐2 is therefore inherently dependent on identifying and isolating infected individuals, especially since COVID‐19 can result in little to no symptoms. Here, we provide a comprehensive review of the different primary technologies used to test for COVID‐19 infection, discuss the advantages and disadvantages of each technology, and highlight the studies that have employed them. We also describe technologies that have the potential to accelerate SARS‐CoV‐2 detection in the future, including digital PCR, CRISPR, and microarray. Finally, remaining challenges in COVID‐19 diagnostic testing are discussed, including (a) the lack of universal standards for diagnostic testing; (b) the identification of appropriate sample collection site(s); (c) the difficulty in performing large population screening; and (d) the limited understanding of SARS‐COV‐2 viral invasion, replication, and transmission. |
format | Online Article Text |
id | pubmed-7443140 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-74431402020-08-28 COVID‐19 diagnostic testing: Technology perspective Xu, Meng Wang, Dan Wang, Hongye Zhang, Xiaomei Liang, Te Dai, Jiayu Li, Meng Zhang, Jiahui Zhang, Kai Xu, Danke Yu, Xiaobo Clin Transl Med Reviews The corona virus disease 2019 (COVID‐19) is a highly contagious disease caused by the severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2). More than 18 million people were infected with a total of 0.7 million deaths in ∼188 countries. Controlling the spread of SARS‐CoV‐2 is therefore inherently dependent on identifying and isolating infected individuals, especially since COVID‐19 can result in little to no symptoms. Here, we provide a comprehensive review of the different primary technologies used to test for COVID‐19 infection, discuss the advantages and disadvantages of each technology, and highlight the studies that have employed them. We also describe technologies that have the potential to accelerate SARS‐CoV‐2 detection in the future, including digital PCR, CRISPR, and microarray. Finally, remaining challenges in COVID‐19 diagnostic testing are discussed, including (a) the lack of universal standards for diagnostic testing; (b) the identification of appropriate sample collection site(s); (c) the difficulty in performing large population screening; and (d) the limited understanding of SARS‐COV‐2 viral invasion, replication, and transmission. John Wiley and Sons Inc. 2020-08-22 /pmc/articles/PMC7443140/ /pubmed/32898340 http://dx.doi.org/10.1002/ctm2.158 Text en © 2020 The Authors. Clinical and Translational Medicine published by John Wiley & Sons Australia, Ltd on behalf of Shanghai Institute of Clinical Bioinformatics This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Reviews Xu, Meng Wang, Dan Wang, Hongye Zhang, Xiaomei Liang, Te Dai, Jiayu Li, Meng Zhang, Jiahui Zhang, Kai Xu, Danke Yu, Xiaobo COVID‐19 diagnostic testing: Technology perspective |
title | COVID‐19 diagnostic testing: Technology perspective |
title_full | COVID‐19 diagnostic testing: Technology perspective |
title_fullStr | COVID‐19 diagnostic testing: Technology perspective |
title_full_unstemmed | COVID‐19 diagnostic testing: Technology perspective |
title_short | COVID‐19 diagnostic testing: Technology perspective |
title_sort | covid‐19 diagnostic testing: technology perspective |
topic | Reviews |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7443140/ https://www.ncbi.nlm.nih.gov/pubmed/32898340 http://dx.doi.org/10.1002/ctm2.158 |
work_keys_str_mv | AT xumeng covid19diagnostictestingtechnologyperspective AT wangdan covid19diagnostictestingtechnologyperspective AT wanghongye covid19diagnostictestingtechnologyperspective AT zhangxiaomei covid19diagnostictestingtechnologyperspective AT liangte covid19diagnostictestingtechnologyperspective AT daijiayu covid19diagnostictestingtechnologyperspective AT limeng covid19diagnostictestingtechnologyperspective AT zhangjiahui covid19diagnostictestingtechnologyperspective AT zhangkai covid19diagnostictestingtechnologyperspective AT xudanke covid19diagnostictestingtechnologyperspective AT yuxiaobo covid19diagnostictestingtechnologyperspective |